Search research articles
Contact Us
Filters
Showing results (51-60 of 85) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Priya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
Sandra M Swain, Gong Tang, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Irene L Wapnir, Karen N Price, Stewart J Anderson, et al.
The Lancet. Oncology
|
August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Eleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Stefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 85) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2019
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
Louis Fehrenbacher, Reena S Cecchini, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2023
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 24, 2024
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Priya Rastogi, Hanna Bandos, Peter C Lucas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial
Sandra M Swain, Gong Tang, Charles E Geyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2018
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Irene L Wapnir, Karen N Price, Stewart J Anderson, et al.
The Lancet. Oncology
|
August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
Eleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
Edward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
The New England Journal of Medicine
|
January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
Harry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology
|
January 21, 2014
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
Stefan Aebi, Shari Gelber, Stewart J Anderson, et al.
Page
of 9